Abstract
Malaria is one of the most prevalent and fatal infectious diseases of the world and is
compounded by wide spread drug resistance, with some strains developing resistance to current front-line anti-malarials. Plasmodium falciparum M1 alanyl aminopeptidase (PFM1AAP) is involved in the terminal stages of haemoglobin degradation and the generation of an amino acid pool to support parasitic growth and development. This represents a promising new anti-malarial target where inhibition of this enzyme is lethal to
compounded by wide spread drug resistance, with some strains developing resistance to current front-line anti-malarials. Plasmodium falciparum M1 alanyl aminopeptidase (PFM1AAP) is involved in the terminal stages of haemoglobin degradation and the generation of an amino acid pool to support parasitic growth and development. This represents a promising new anti-malarial target where inhibition of this enzyme is lethal to
Original language | English |
---|---|
Pages (from-to) | 354a |
Number of pages | 1 |
Journal | Biophysical Journal |
Volume | 112 |
Issue number | 3 (Supplement 1) |
DOIs | |
Publication status | Published - 03 Feb 2017 |